TAS102 in Combination With NAL-IRI in Advanced GI Cancers
Status:
Recruiting
Trial end date:
2022-11-28
Target enrollment:
Participant gender:
Summary
This phase I/II trial studies the best dose and how well trifluridine/tipiracil hydrochloride
combination agent TAS-102 (TAS-102) and nanoliposomal irinotecan work in treating patients
with gastrointestinal cancers that have spread to other places in the body (metastatic) or
cannot be removed by surgery. Drugs used in the chemotherapy, such as trifluridine/tipiracil
hydrochloride combination agent TAS-102 and nanoliposomal irinotecan, work in different ways
to stop the growth of tumor cells, either by killing the cells, by stopping them from
dividing, or by stopping them from spreading.